DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181017

The relation of serum GGT level in patients with non valvular atrial fibrillation and normal sinus rhythm

C. L. Nawal, Radhey Shyam Chejara, Ankush Panwar, M. K. Agrawal, Aradhana Singh, P. D. Meena

Abstract


Background: The primary objective of the study was to assess and compare the relation of serum GGT level in patients with non valvular atrial fibrillation and normal sinus rhythm. The fundamental mechanisms underlying AF remains poorly understood. Oxidative stress is hypothesized to induce and maintain nonvalvular atrial fibrillation particularly in elderly patients. GGT levels are increased in patients with chronic inflammation. Increased serum levels of GGT are found in chronic nonvalvular atrial fibrillation (AF) patients as compared with patients in sinus rhythm.

Methods: We included 75 patients of nonvalvular atrial fibrillation and 75 patients of sinus rhythm after applying exclusion criteria. Serum level of gamma glutamyl transrerase (GGT) of both the groups was compared.

Results: Presence of coronary artery disease, hypertension, gender, hyperlipidemia, diabetes mellitus and smoking status were comparable between the 2 groups (P > 0.05 for all). Serum gamma glutamyl transferase activity in 75 cases was 71.45±26.21 with maximum being 147 IU/L more than the normal range for age, whereas in controls it was 19.68±5.53 i.e. much within the normal range for age.

Conclusions: At the end of the study we concluded that serum GGT levels were significantly higher in patients with chronic nonvalvular atrial fibrillation (AF) patients as compared with patients in sinus rhythm.


Keywords


Atrial Fibrillation (AF), Gamma Glutamyl Transferase (GGT)

Full Text:

PDF

References


Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Ame Coll Cardiol. 2001;37(2):371-8.

Tekin G, Tekin YK, Senarslan DA, Gocmen AY, Senarslan O, Erbay AR. Serum γ-glutamyltransferase activity in patients with nonvalvular atrial fibrillation. Angiology. 2013;64(2):157-60.

Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Ame J Cardiol. 1994;74(3):236-41.

Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circulation J. 2015;79(3):495-502.

Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Ame Coll Cardiol. 2007;50(21):2021-8.

Allessie MA, Boyden PA, Camm AJ, Kléber AG, Legato MJ, Rosen MR, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103(5):769-77.

Semenov AV, Kogan-Ponomarev MIa, Ruda MIa, Komarov AL, Panchenko EP, Chazova IE, Mazurov AV. Soluble P-selectin-a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension. Ter Arkh. 2000;72(4):15-20.

Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C, et al. Prothrombin fragment F1+ 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood coagulation fibrinolysis: an Inter J Haemostasis Thrombosis. 1992;3(4):469-73.

Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arteriosclerosis, thrombosis, and vascular biology. 2007;27(1):127-33.

Benjamin EJ, Levy D, Vaziri SM, D'agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840-4.

Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia. 2003;46(3):359-64.

Yamada J, Tomiyama H, Yambe M, Koji Y, Motobe K, Shiina K, et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006;189(1):198-205.

Whitfield JB. Gamma-glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263-355.

Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR, Jr. Lee DH. Is serum gamma glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med. 2004;37(7):1018-23.

Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Annals Translational Med. 2016 Dec;4(24):481.